Labcorp Drug Development Inc. Sustainability Profile
Labcorp Drug Development Inc., a prominent player in the global life sciences industry, is headquartered in the United States. Founded in 1971, the company has established itself as a leader in drug development and laboratory services, providing comprehensive solutions to pharmaceutical and biotechnology clients. With a strong presence across North America, Europe, and Asia, Labcorp offers a wide range of services, including clinical trial management, laboratory testing, and biomarker development. Renowned for its innovative approach, Labcorp's core offerings are distinguished by advanced technology and a commitment to improving patient outcomes. The company has achieved significant milestones, including the successful management of thousands of clinical trials and the integration of cutting-edge diagnostics. As a trusted partner in the drug development process, Labcorp continues to enhance its market position through strategic collaborations and a focus on scientific excellence.
DitchCarbon Score
How does Labcorp Drug Development Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Labcorp Drug Development Inc.'s score of 69 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Labcorp Drug Development Inc., headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Labcorp Holdings Inc., which may influence its climate commitments and reporting practices. Labcorp Drug Development Inc. inherits its climate initiatives and targets from Labcorp Holdings Inc. at a cascade level of 1. However, there are no documented reduction targets or significant climate pledges available for Labcorp Drug Development Inc. at this time. This lack of specific data suggests that the company may still be in the process of establishing or formalising its climate strategy. In the broader context, companies in the pharmaceutical and drug development sector are increasingly focusing on sustainability and carbon reduction, often aligning with industry standards such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). As Labcorp Drug Development Inc. continues to develop its climate commitments, it may adopt similar frameworks to enhance its environmental performance and transparency.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 69,115,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 178,899,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Labcorp Drug Development Inc.'s Industry?
How Carbon Intensive is Labcorp Drug Development Inc.'s Location?
Labcorp Drug Development Inc.'s Scope 3 Categories Breakdown
Labcorp Drug Development Inc.'s Scope 3 emissions, which decreased by 4% last year and increased by approximately 10% since 2020, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 76% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 54% of Scope 3 emissions.
Top Scope 3 Categories
Labcorp Drug Development Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Labcorp Drug Development Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
